MDxHealth SA ADR
$ 3.55
-1.66%
24 Feb - close price
- Market Cap 185,426,000 USD
- Current Price $ 3.55
- High / Low $ 3.67 / 3.51
- Stock P/E N/A
- Book Value -0.16
- EPS -0.52
- Next Earning Report 2026-02-26
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.06 %
- ROE -7.20 %
- 52 Week High 5.33
- 52 Week Low 1.35
About
MDxHealth SA is a leading biotechnology company that specializes in precision diagnostic solutions aimed at improving cancer management, primarily for prostate and bladder cancers. Utilizing cutting-edge molecular technologies, the company has developed and commercialized significant diagnostic tests, including its flagship product, ConfirmMDx for Prostate Cancer, which has shown considerable clinical utility and market acceptance. As the landscape of personalized medicine evolves and the demand for tailored cancer treatment increases, MDxHealth is strategically positioned to leverage its innovative capabilities and broaden its portfolio, targeting critical unmet needs within oncology and enhancing patient outcomes.
Analyst Target Price
$7.40
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-11-12 | 2025-08-14 | 2025-05-14 | 2025-02-26 | 2024-11-06 | 2024-08-21 | 2024-05-01 | 2024-03-06 | 2023-11-08 | 2023-08-23 | 2023-05-15 | 2023-03-09 |
| Reported EPS | -0.16 | -0.14 | -0.19 | -0.14 | -0.4 | -0.42 | -0.31 | -0.39 | -0.4 | -0.3 | -0.5 | -1.1 |
| Estimated EPS | -0.17 | -0.12 | -0.13 | -0.19 | -0.25 | -0.26 | -0.3 | -0.11 | -0.19 | -0.22 | -0.5 | -0.65 |
| Surprise | 0.01 | -0.02 | -0.06 | 0.05 | -0.15 | -0.16 | -0.01 | -0.28 | -0.21 | -0.08 | 0 | -0.45 |
| Surprise Percentage | 5.8824% | -16.6667% | -46.1538% | 26.3158% | -60% | -61.5385% | -3.3333% | -254.5455% | -110.5263% | -36.3636% | 0% | -69.2308% |
Next Quarterly Earnings
| Dec 2025 | |
|---|---|
| Reported Date | 2026-02-26 |
| Fiscal Date Ending | 2025-12-31 |
| Estimated EPS | -0.13 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: MDXH
2026-02-23 01:45:13
MDxHealth SA (MDXH) is transforming into a commercial-stage company focused on urologic cancers, aiming for profitability by 2027 with its "ExoDx" and "GPS" tests. The company reported strong preliminary 2025 revenue of $109 million, projects up to $140 million for 2026, and seeks a 10% adjusted EBITDA margin by year-end 2026, supported by a recent amended earnout agreement. Despite its "high-beta" nature, the stock is considered undervalued at $3.63, with an author's fair value of $4.18, suggesting a potential re-rating as it shifts from a loss-making biotech to a profitable diagnostics leader.
2026-02-21 08:53:32
MDxHealth SA (NASDAQ:MDXH) has received an average "Moderate Buy" rating from analysts, with an average one-year price target of $7.75. This consensus stems from five research firms, including one sell rating and four buy ratings. The molecular diagnostics company, focusing on urological cancers, opened at $3.63 with a market cap of $171.7M and a negative P/E of -5.67.
2026-02-19 06:56:59
MDxHealth (NASDAQ: MDXH) is anticipated to release its Q4 2025 earnings after market close on Thursday, February 26th, with analysts forecasting a loss of ($0.13) per share and $26.05 million in revenue. The stock opened at $3.68 and has a "Moderate Buy" consensus rating from analysts, with an average price target of $7.75. Several hedge funds have recently adjusted their stakes in MDXH, and analyst price targets have been increased.
2026-02-13 06:57:40
MDxHealth SA (NASDAQ: MDXH) announced it will release its financial results for the fourth quarter and full year ended December 31, 2025, after market close on Thursday, February 26, 2026. The company will host a conference call and webcast with live Q&A on the same day at 4:30 PM ET to discuss the results and provide a corporate update. MDxHealth is a precision diagnostics company specializing in urologic cancers and diseases.
2026-02-12 21:57:40
MDxHealth (NASDAQ: MDXH) will release its financial results for the fourth quarter and full year ended December 31, 2025, on February 26, 2026, after market close. The company will host a conference call and webcast on the same day at 4:30 PM ET (22:30 CET), offering a live Q&A session. MDxHealth specializes in precision diagnostics for urologic cancers and other diseases, operating in the U.S. and Europe.
2026-02-01 00:31:00
MDxHealth SA (NASDAQ:MDXH) experienced a significant decline in short interest in January, with holdings falling 34.8% to 25,720 shares, representing only 0.1% of shares outstanding. The company has a "Moderate Buy" consensus rating from analysts with a price target of $7.75, despite recently missing EPS expectations while beating revenue estimates. MDxHealth remains unprofitable, with analysts forecasting an EPS of -1.15 for the current fiscal year.
